Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide to prevent post-transplantation diabetes after kidney transplantation
2026-525910-77-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of semaglutide in post-transplantation diabetes mellitus (PTDM), sponsored by Radboud University Medical Center. Primary endpoint: Occurrence of post-transplantation diabetes mellitus. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on 2026-525910-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525910-77-00.